Vimta Labs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹112 Cr +9.8% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
VL

Vimta Labs Ltd

Q2 FY26Healthcare Services

Vimta Labs Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹102Cr
+20% YoY
+4.1% QoQ
Net profit
₹20Cr
+33.3% YoY
+5.3% QoQ
Margin
34%
−1 pp YoY
−1 pp QoQ
Price₹630
Market cap₹2.8K Cr
P/E34.1

The short version

Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.

From Vimta Labs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors.
  • All verticals—pharma, food, electronics—are anticipated to grow at similar rates (7.5% to 9%), with pharma dominating revenue share (~65%) and food contributing ~20%.
  • Biologics and large molecule formulation development services are emerging growth areas, with commercialization expected by Q1 FY 2027.
  • Expansion in capacity across all verticals (pharma, food, electronics, preclinical, GMP testing) has been done to support growth without immediate capacity constraints.
  • Increasing client demand for biologics development and outsourcing trends will further boost pharma segment growth.
  • International markets offer opportunities for new business and market share gain, particularly in pharma.

2 more points from Vimta Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.
  • Biologics segment capex is around INR25 crores for this year, with a similar amount planned for the next year ('27).
  • Capex is spread across pharmaceuticals, food, and electrical & electronic testing verticals.
  • Investments focus on expanding capacities, including new equipment and infrastructure.
  • Some capex backed by visibility from client pipelines; others are inherent to newly created capacities.
  • Clinical research requires minimal capex as studies in patient populations are off-site.

2 more points from Vimta Labs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • They mentioned having strong order pipelines, especially in the pharmaceutical segment, mainly supporting generic product development.
  • Preclinical business supports both discovery (35%) and generic, specialty chemicals, regulatory work (65%).
  • The clinical trial business pipeline is growing, with intensified business development operations.
  • The newly added CMO/CRADS vertical is part of the expansion backed by visibility of pipelines and client interest.
  • Expansion into biologics and formulation development is driven by growing demand and client requests.

2 more points from Vimta Labs Ltd's call on order book

Create a free account to keep reading this call

Vimta Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Vimta Labs Ltd Q2 FY26 results — key figures

Vimta Labs Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue10285+20%98+4.1%
Operating profit (EBITDA)3430+13.3%340%
Operating margin34%35%-1 pp35%-1 pp
Profit before tax2620+30%25+4%
Net profit (PAT)2015+33.3%19+5.3%
EPS (₹)4.473.44+29.9%4.24+5.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Maitreya Medicare (Q2 FY26)

    23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.

  • Metropolis Healt (Q2 FY26)

    Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…

  • 3B Blackbio (Q2 FY26)

    Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…

  • Unihealth Hosp (Q2 FY26)

    Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vimta Labs Ltd Q2 FY26 results?

Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.

What is Vimta Labs Ltd share price analysis?

Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vimta Labs Ltd planning capital expenditure?

Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.

Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.